Contenido Relacionado

Contenido en el Idioma Español de University of Maryland Medical Center

Pruebas de detección para recién nacidos - Resultados

Nombres alternativos

Exámenes de tamizaje para bebés; Pruebas de detección para neonatos

Valores normales:

Los valores normales para cada prueba de detección pueden variar dependiendo de la forma como se realice dicha prueba.

Significado de los resultados anormales:

Un resultado anormal no significa que el bebé tenga la enfermedad indicada. En general, la mayoría de los bebés que tienen un resultado anormal en el examen resultan no teniendo la enfermedad. Sin embargo, un resultado anormal no significa que el niño deba someterse a pruebas adicionales para confirmar o descartar la condición.

Fecha de revisión: 9/6/2007
Versión en inglés revisada por:Alan Greene, M.D., F.A.A.P., Department of Pediatrics, Stanford School of Medicine; Lucile Packard Children's Hospital; Chief Medical Officer, A.D.A.M., Inc., and Deirdre O’Reilly, M.D., M.P.H., Neonatologist, Division of Newborn Medicine, Children’s Hospital Boston and Instructor in Pediatrics, Harvard Medical School, Boston, Massachusetts.
Traducción y localización realizada por: DrTango, Inc

Referencias

American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics. 2006 May;117(5 Pt 2):S296-307.

Graves JC, Miller KE, Sellers AD. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002 Mar 1;65(5):915-20.

Grosse SD, Boyle CA, Cordero JF. Newborn screening for cystic fibrosis: recommendations from the Centers for Disease Control and Prevention. Am Fam Physician. 2005 Apr 15;71(8):1482, 1487.

Bryant KG, Horns KM, Longo N, Schiefelbein J. A primer on newborn screening. Adv Neonatal Care. 2004 Oct;4(5):306-17.

Carreiro-Lewandowski E. Newborn screening: an overview. Clin Lab Sci. 2002 Fall;15(4):229-38.

Centers for Disease Control and Prevention. Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs. J Pediatr. 2005 Sep;147(3 Suppl):S1.

Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004 Oct 15;53(RR-13):1-36.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.